Arvinas Estrogen Receptor, Inc.
Clinical trials sponsored by Arvinas Estrogen Receptor, Inc., explained in plain language.
-
New combo therapy shows promise in early breast cancer trial
Disease control CompletedThis early-phase trial tested a new drug, ARV-471, combined with everolimus in 32 people with advanced ER+/HER2- breast cancer that had stopped responding to other treatments. The main goals were to check safety and find the best dose. This is not a cure, but aims to better contr…
Phase: PHASE1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
New hope for advanced breast cancer: experimental drug ARV-471 shows promise in early trial
Disease control CompletedThis study tested an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 people with a common type of advanced breast cancer (ER+/HER2-) that had stopped responding to standard treatments. The main goals were to check safety and see if the drug shri…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC